- Home >
- Investors
Investors
Our business model is designed to bring solutions to patients while generating shareholder value, by translating our proprietary technology into commercial drug products in a rapid and cost-effective way.
Investment case
Silence has been a pioneer in the RNAi field for over 18 years. Through the efforts of our skilled researchers and scientists, we have established an innovative platform with broad intellectual property protection. Using our RNAi-directed platform technologies, we have generated siRNA product candidates both for our internal development pipeline as well as for out-licensed programs with third-party collaborators. We are currently focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron overload disorders, and complement-mediated disorders.
Results, reports & presentations
Annual Report 2019
DownloadHalf Year Results 2020
391KB DownloadFull Year Results 2019
361KB DownloadHalf Year Results 2019
345KB DownloadFull Year Results 2018
371KB DownloadHalf Year Results 2018
367KB DownloadAnnual Report 2019
1MB DownloadAnnual Report 2018
3MB DownloadAnnual Report 2017
2MB DownloadAnnual Report 2016
1MB DownloadAnnual Report 2015
978KB DownloadSilence Therapeutics FY19 Results Announcement
175KB DownloadCollaboration with AstraZeneca and R&D Update
176KB DownloadSilence Therapeutics HY20 Results Announcement
Click here to register for the webcast
955KB DownloadSilence Therapeutics Fireside Chat at the RBC Capital Markets Global Healthcare Virtual Conference
Click here to replay the webcast
163KB DownloadCorporate governance
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.